Navigation Links
Frazier Healthcare Adds Carol Gallagher to its Life Science Team
Date:10/29/2013

MENLO PARK, Calif., Oct. 29, 2013 /PRNewswire-iReach/ -- Frazier Healthcare, a leading provider of venture and growth buyout capital to emerging healthcare companies, announced today that Carol Gallagher Pharm.D., former CEO of Calistoga Pharmaceuticals, has joined the Frazier Healthcare team as a Venture Partner.

Dr. Gallagher has a long and distinguished track record as an entrepreneur, executive, and drug developer. She started her career at Eli Lilly, and subsequently held senior positions at Biogen-Idec, Agouron Pharmaceuticals, CancerVax and Anadys Pharmaceuticals. Most recently, she was the CEO of Calistoga Pharmaceuticals, a Frazier-founded company based on a set of novel, preclinical assets spun out of Icos Pharmaceuticals. Dr. Gallagher joined the company in 2008 as the CEO, and together with an experienced team she helped to build, advanced a first-in-class product (CAL-101, now called idelalisib) through definitive, proof-of-concept studies in patients with certain lymphomas and leukemias. These efforts ultimately led to the acquisition of Calistoga by Gilead Sciences in 2011 for a total consideration of $600 million, and Gilead has filed for FDA approval of idelalisib in Q3 2013. Dr. Gallagher currently serves on several biotech boards, including AnaptysBio and Atterocor, both of which are Frazier portfolio companies.

"I have had a great working relationship with the Frazier Healthcare team for many years. Their approach to building innovative companies focused on unmet clinical needs is aligned with my own and I am very pleased to join them as a Venture Partner" commented Dr. Gallagher.

"We are thrilled to have Carol join our life science team. Her experience ranges from early stage drug development through successful commercialization strategies, and we are excited about leveraging those skills to continue our successes in life science investing," commented Jamie Topper, General Partner.

"We have known and worked with Carol over the past 15 years through collaboration on several successful investments. We are pleased to have her join our team as we invest our Frazier Healthcare VII capital," commented Patrick Heron, General Partner

Frazier Healthcare recently completed the fundraising effort for its seventh healthcare fund, Frazier Healthcare VII, surpassing its fund target of $300 million with commitments of $377 million.

About Frazier Healthcare

Founded in 1991, Frazier Healthcare is a leading provider of venture and growth buyout capital to emerging healthcare service and biopharma companies. With over $2 billion under management across seven funds, Frazier Healthcare has invested in more than 150 companies across the entire developmental spectrum. From venture investments to leveraged recapitalizations, Frazier Healthcare has established itself among entrepreneurs and seasoned executives as a preferred partner to help create and grow successful healthcare companies. The Life Science team at Frazier Healthcare focuses on investments in Biopharmaceuticals and related areas that are addressing areas of unmet medical need through innovation.

For more information about Frazier Healthcare, visit the company's website at www.frazierhealthcare.com.  

Press Contact
Frazier Healthcare
Bridget Rauvola – Marketing & Investor Relations Partner
Phone: 206.254.116
Cell: 303.775.2929
Email: Bridget.rauvola@frazierhealthcare.com 

Media Contact: Bridget Rauvola, Frazier Healthcare, 303.775.2929, bridget.rauvola@frazierhealthcare.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Frazier Healthcare
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Healthcare Biometrics Market is Expected to Reach USD 5.8 Billion Globally in 2019: Transparency Market Research
2. ChipCares handheld analyzer attracts one of Canadas largest-ever healthcare angel investments
3. TGen and Scottsdale Healthcare launch Phase I Thunder God vine trial for cancer
4. NIH program explores the use of genomic sequencing in newborn healthcare
5. Notre Dame researchers develop system that uses a big data approach to personalized healthcare
6. Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board
7. Nurses at forefront of genomics in healthcare
8. TGen, Scottsdale Healthcare study shows drug combination extends pancreatic cancer patient survival
9. Mount Sinai grad student, 25, named to Forbes 30 Under 30 in Science and Healthcare
10. BUSM/VA Boston Healthcare System investigators identify new gene linked to PTSD
11. Pilot Results Move GHX Closer to Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... Atlanta, it seems everyone has a chance to express their ... expressive and dynamic community unlike any other. The businesses that ... With their newest salon in ... on that tradition with a unique, fresh approach to head ... the newest of 13 nationwide locations, each of them well-situated ...
Breaking Biology Technology: